- RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE1
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
This study looks at a new combination treatment, venetoclax and azacitidine, for people in the UK with a higher-risk type of blood cancer called Myelodysplastic Syndromes (MDS) who haven't had treatment before. It's an early-stage study to find the best dose.
For: Myelodysplastic Syndromes (MDS)United States · Australia · Canada - RecruitingPHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
This study looks at a new way to re-treat a type of blood cancer called CLL when it returns. It uses two approved medicines, venetoclax and obinutuzumab, in adults who have had previous venetoclax treatment.
For: Chronic Lymphocytic Leukemia (CLL)United States · Australia · Austria - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Brazil - RecruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
For: Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myelodysplastic Syndrome/NeoplasmUnited States · Canada · Czechia - RecruitingPHASE1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study looks at a new treatment called mosunetuzumab for chronic lymphocytic leukemia (CLL) that has come back or not responded to previous treatments. It checks how safe it is, how well it works, and how the body handles it, sometimes used with another drug, venetoclax.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · China - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
For: Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study is looking at two different medicine combinations for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). We want to see if a newer treatment works better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-CellUnited States · Belgium · Canada - Active not recruitingPHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
This study looks at a new combination of three chemotherapy-free drugs for people newly diagnosed with Mantle Cell Lymphoma. It aims to see if this treatment can clear the cancer and if some people can then stop treatment or use just one drug.
For: Mantle Cell Lymphoma (MCL)United States · Australia · Brazil - Active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
For: CLLUnited States · Australia · Austria - Active not recruitingPHASE3
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
This study compares two treatments, Venetoclax plus Dexamethasone, and Pomalidomide plus Dexamethasone, for people with a specific type of multiple myeloma (t(11;14)-positive) that has come back or not responded to previous treatments. It aims to see which treatment works best at preventing the disease from getting worse.
For: Multiple MyelomaUnited States · Australia · Canada - Active not recruitingPHASE1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
This study is looking into a new medicine, ABBV-101, for blood cancers called non-Hodgkin's lymphoma (NHL). It will check how safe the medicine is, how it moves through the body, and if it helps people with different types of NHL that have come back or not responded to other treatments.
For: Hematologic CancerUnited States · Canada · France - RecruitingPHASE1, PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesAustralia · Netherlands · United Kingdom - RecruitingPHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
This study looks at a new drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares BGB-16673 to existing treatments in patients whose cancer has come back after trying two other types of drugs.
For: CLL · Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - RecruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
For: Acute Myeloid LeukemiaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
This study compares a new drug, zanubrutinib, with standard treatments (bendamustine and rituximab) for adults with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL). Researchers want to see which treatment works best to stop the cancer from getting worse.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
For: Chronic Lymphocytic Leukemia · Acute Myeloid Leukemia · Multiple MyelomaUnited States · Australia · Austria - RecruitingPHASE3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This study looks at new ways to treat Chronic Lymphocytic Leukemia (CLL), a type of blood cancer. Researchers are testing the safety of two drug combinations: venetoclax with obinutuzumab, or venetoclax with acalabrutinib. They want to see how well these treatments work and if they cause any side effects.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · France - RecruitingPHASE3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
This study is testing a new drug, ziftomenib, for a type of blood cancer called AML. It combines ziftomenib with standard treatments for patients who haven't had treatment before, aiming to see if it works better than usual care alone.
For: Acute Myeloid Leukemia (AML)United States · Czechia · France - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
For: Myelodysplastic Syndrome (MDS)United States · Australia · Austria - Active not recruitingPHASE1, PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.
For: Acute Myeloid LeukemiaUnited States · France · Germany - Active not recruitingPHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two treatments, Acalabrutinib plus Venetoclax vs. Venetoclax plus Obinutuzumab, for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's checking which combination works better and is safer.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · Czechia - Active not recruitingPHASE3
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
This study looks at a new drug, galinpepimut-S, for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) who are in remission. It compares the new drug to standard treatments to see if it helps people live longer.
For: Acute Myeloid LeukemiaUnited States · France · Germany - RecruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
For: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin LymphomaUnited States · France · Spain - RecruitingPHASE3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
This study is looking at a new combination of treatments for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It compares a new drug called Nemtabrutinib with Venetoclax against a standard treatment, to see if the new combination is better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
For: Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Acute · Multiple MyelomaUnited States · Belgium · Canada - Active not recruitingPHASE3
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This study compares a new treatment, Pirtobrutinib, with standard drugs (Venetoclax and Rituximab) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who’ve had treatment before. Researchers want to see if the new combination works better and is safe.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - RecruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This study looks at new ways to treat a serious type of blood cancer called AML in people aged 18-59. It compares standard treatment with newer drug combinations to see if they work better at shrinking the cancer.
For: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States · Canada · Puerto Rico - RecruitingPHASE3
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This study compares two treatments for high-risk chronic lymphocytic leukaemia (CLL). One involves three drugs, and the other uses two. It aims to see if the three-drug combination can better prevent the disease from getting worse.
For: Chronic Lymphocytic LeukemiaGermany - Active not recruitingPHASE1
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
This study looks at a new drug called cusatuzumab, given with standard treatments, for people newly diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to find out how safe these treatments are together and if people can tolerate them well.
For: Leukemia, Myeloid, AcuteUnited States · Canada · Germany - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium - RecruitingPHASE3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
This study is for adults aged 18-75 recently diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML) or certain types of Myelodysplastic Syndrome. It tests a new drug, venetoclax, alongside standard chemotherapy, to see if this combination works better than chemotherapy alone.
For: Acute Myeloid LeukemiaAustria · Belgium · Estonia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Venetoclax after TKI to target persisting stem cells in CML
This study looks at a new way to treat Chronic Myeloid Leukaemia (CML). It's for people whose CML is well controlled with standard medicine. Researchers want to see if adding another drug, Venetoclax, can get rid of the remaining leukaemia cells that might be hiding in the bone marrow.
For: Chronic Myeloid LeukemiaGermany - RecruitingPHASE1, PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study looks at new treatments for children and young adults with specific types of blood cancer that have come back or not responded to previous treatment. It tests a combination of medicines to see if they are safe and work well for those whose cancer has certain genetic changes.
For: Acute Lymphoblastic Leukemia, in Relapse · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark - Active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
For: Acute Myeloid Leukemia · Chronic Myelomonocytic Leukemia · Myelodysplastic SyndromesUnited States · Finland · United Kingdom - RecruitingPHASE1, PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
This study is for children and young adults aged 1-21 with specific types of aggressive blood cancers that have come back or not responded to treatment. It tests new drug combinations to see if they're safe and work well for those with certain genetic changes in their cancer.
For: Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent · Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentAustria · Belgium · Denmark